Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists

Kelsey B. Nusbaum, Brittany Dulmage, Jennifer N. Choi, Samantha M. Jaglowski, Abraham M. Korman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Chimeric antigen receptor T-cell therapy is an emerging immunotherapy with promising efficacy for the treatment of previously refractory or relapsed malignancies. As a personalized medicine approach, T cells are genetically engineered to express a receptor designed to bind a specific tumor antigen, leading to selective immune-mediated destruction of tumor cells. Due to the novelty of chimeric antigen receptor T-cell therapy, the safety profile continues to evolve with limited information currently available on cutaneous adverse events. Improved understanding of the spectrum of cutaneous adverse events may facilitate earlier recognition and appropriate management of these toxicities. To explore this knowledge gap, we discuss the available case reports and clinical trial results of cutaneous reactions associated with chimeric antigen receptor T-cell therapy.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
DOIs
StateAccepted/In press - 2021

Keywords

  • CAR T
  • chimeric antigen receptor T-cell therapy
  • cutaneous reactions
  • immunotherapy
  • skin toxicity

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists'. Together they form a unique fingerprint.

Cite this